Welcome to our dedicated page for Nuvasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on Nuvasive stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvasive's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvasive's position in the market.
NuVasive, Inc. (NASDAQ: NUVA) announced a study validating the use of its MaXcess® retractor for prone, single-position lateral interbody fusion, published in The Journal of Neurosurgery: Spine.
The study demonstrates successful outcomes in 11 of 12 patients treated, contributing to the evidence supporting this surgical approach. It shows a commitment to innovative spine surgery solutions, highlighting the potential for increased efficiency and reduced operative time while noting some limitations for patient eligibility. The X360™ system's value was also emphasized.
NuVasive, Inc. (NASDAQ: NUVA) has announced the limited availability of the new Precice® Plate, a groundbreaking solution for limb lengthening and reconstruction, specifically designed for pediatric patients. This innovative device allows for internal lengthening while protecting growth plates, enhancing comfort compared to traditional external fixators. The Precice Plate can be adjusted remotely at home, promoting better patient outcomes. Full commercial launch is expected in early 2021 across the US and Europe, marking a significant advancement in pediatric orthopedic care.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology, announced its participation in three virtual investor events in September 2020. The events include:
- Wells Fargo Securities 2020 Virtual Healthcare Conference on September 9
- Baird 2020 Virtual Global Healthcare Conference on September 10
- Morgan Stanley 18th Annual Virtual Global Healthcare Conference on September 14
Webcasts of each presentation will be available on their Investor Relations page, with replays accessible for 30 days post-event.
NuVasive, Inc. (NASDAQ: NUVA) reported a 30.3% decline in net sales for Q2 2020, totaling $203.6 million, compared to $292.1 million in Q2 2019. The company experienced a GAAP net loss of $50.0 million, or $0.98 per share, markedly worse than the net income of $15.0 million reported in the previous year. Non-GAAP results showed a net loss of $20.4 million, or $0.40 per share. Despite a positive sales trend in June, the company refrained from providing annual financial guidance due to ongoing uncertainty regarding elective surgery volumes amid the COVID-19 pandemic.
NuVasive (NASDAQ: NUVA) has launched the Time to Evolve campaign, advocating for the adoption of less invasive spine surgery techniques. The company highlights its XLIF procedure, proven via over 500 peer-reviewed studies, to enhance clinical outcomes with a fusion rate of up to 100% and a 90% reduction in blood loss. The initiative aims to improve operational efficiency and reduce hospital costs by up to 10%. NuVasive's commitment to innovation is evidenced by its comprehensive procedural portfolio designed for better patient outcomes.
NuVasive (NASDAQ: NUVA) reported preliminary second-quarter 2020 results, estimating net sales between $202 million and $205 million, a 30% decrease from $292.1 million in Q2 2019, largely due to the COVID-19 pandemic's impact on elective surgeries. The company expects operating losses between $35 million and $40 million on a GAAP basis, along with $20 million to $25 million in pandemic-related charges. Despite the downturn, NuVasive noted a recovery in surgical volumes as restrictions eased, and had over $920 million in cash and equivalents as of June 30, 2020.
NuVasive, Inc. (NASDAQ: NUVA) has become the first industry sponsor of the American Spine Registry (ASR) in a multi-year collaboration aimed at enhancing spine surgery through data-driven outcomes. This partnership is poised to improve evidence-based decision-making for over 1.2 million spine surgeries performed annually in the U.S. NuVasive will support data collection for quality tracking and benchmarking, benefitting spine surgeons and contributing to better patient outcomes.
NuVasive, Inc. (NASDAQ: NUVA) announced the global commercial launch of Reline 3D, a posterior fixation system designed for the treatment of pediatric spinal deformities, particularly adolescent idiopathic scoliosis (AIS). This innovative system simplifies complex surgical procedures by allowing simultaneous correction of three-dimensional spinal deformities, enhancing efficiency for surgeons. Reline 3D is now available in the US and Europe, with plans to expand to additional markets next year. This launch underscores NuVasive’s commitment to advancing surgical techniques and improving patient outcomes.